Arrowhead gets FDA approval for rare lipid disease drug

The FDA has approved Arrowhead Pharmaceuticals’ Redemplo for a rare disease in which patients can't break down certain fat molecules, setting up a rivalry between the company and Ionis. The new entrant will have to ...